(Heart) Cardiac Stent Price in Bangladesh 2026: Latest Price

Discover the updated Cardiac Stent Price in Bangladesh 2026, DGDA price cuts, transparent billing rules, and affordable heart care for patients.

Introduction

Cardiovascular disease remains one of the leading causes of death worldwide, and Bangladesh is no exception. Every year, thousands of Bangladeshis suffer from coronary artery disease (CAD), heart attacks, and other cardiovascular complications requiring advanced medical intervention. Among the most common and life-saving treatments is the implantation of a coronary stent, commonly known as a “heart ring.”

In June 2026, the Directorate General of Drug Administration (DGDA) took a significant step toward improving healthcare affordability by reducing the maximum retail prices (MRP) of several cardiac stents available in Bangladesh. The price reduction ranges from BDT 3,000 to BDT 47,800 depending on the stent model, with the largest reduction applied to the Silene Covered Stent.

The decision has generated widespread discussion among healthcare professionals, hospitals, patients, and policymakers. Beyond merely reducing prices, the DGDA has also introduced stricter transparency measures aimed at protecting patients from excessive billing and hidden charges.

This move marks an important milestone in Bangladesh’s efforts to make advanced cardiac care more accessible and affordable for all citizens.

What is Cardiac Stents?

A cardiac stent is a small expandable mesh tube inserted into narrowed or blocked coronary arteries to restore blood flow to the heart muscle.

When cholesterol, fat, calcium, and inflammatory materials accumulate within coronary arteries, a condition known as atherosclerosis develops. Over time, these deposits create blockages that reduce blood flow and increase the risk of heart attacks.

A stent acts as a scaffold, keeping the artery open after a balloon angioplasty procedure.

How a Stent Works

The procedure generally involves:

Performing coronary angiography to identify blockages.
Inserting a catheter through the wrist or groin artery.
Expanding a balloon at the blockage site.
Deploying the stent to support the artery wall.
Removing the catheter while leaving the stent permanently in place.

The entire procedure is commonly known as Percutaneous Coronary Intervention (PCI) or coronary angioplasty.

Who Needs a Cardiac Stent?

Who Needs a Cardiac Stent?

Not every patient with heart disease requires a cardiac stent. The decision to place a stent depends on the severity of the blockage, the patient’s symptoms, and the results of diagnostic tests. A cardiologist carefully evaluates each case before recommending the procedure.

Common Indications for Cardiac Stent Placement

1. Significant Coronary Artery Blockage

Patients with severe narrowing (typically 70% or greater) in one or more major coronary arteries may benefit from a stent to improve blood flow to the heart muscle.

2. Acute Heart Attack (Myocardial Infarction)

During a heart attack, a blocked coronary artery requires immediate treatment. Emergency stent placement can quickly restore blood flow, reduce heart muscle damage, and improve survival.

3. Persistent Angina (Chest Pain)

If chest pain continues despite lifestyle modifications and optimal medical treatment, a cardiac stent may help relieve symptoms and improve quality of life.

4. High-Risk Coronary Lesions

Certain types of coronary artery blockages—such as critical narrowings in major vessels or anatomically complex lesions—carry a higher risk of future cardiac events and may require stent implantation.

5. Restenosis (Re-Narrowing of an Artery)

In some patients, a previously treated artery may become narrowed again. Depending on the cause and severity, an additional stent or another interventional procedure may be recommended.

Important Note

A cardiac stent is not the best treatment for every patient with coronary artery disease. In some cases, medications, lifestyle changes, or coronary artery bypass surgery (CABG) may provide better long-term outcomes. The most appropriate treatment should always be determined by a qualified cardiologist based on the patient’s overall condition and clinical findings.

Types of Cardiac Stents

Advances in interventional cardiology have led to the development of several types of cardiac stents, each designed for specific clinical situations. The choice of stent depends on the patient’s condition, the characteristics of the coronary artery blockage, and the cardiologist’s assessment.

1. Bare Metal Stents (BMS)

Bare Metal Stents (BMS) are simple metallic mesh tubes that provide structural support to keep a narrowed coronary artery open. Unlike newer stents, they do not contain a drug coating.

Advantages

Lower initial cost
Require a shorter duration of dual antiplatelet therapy (DAPT) in selected patients
Effective in certain clinical situations where prolonged blood-thinning medication is not suitable

Disadvantages

Higher risk of restenosis (re-narrowing of the artery)
Greater likelihood of requiring repeat procedures
Less commonly used today due to the availability of more advanced stent technologies

2. Drug-Eluting Stents (DES)

Drug-Eluting Stents (DES) are coated with medications that are gradually released into the artery after implantation. These drugs help prevent excessive scar tissue formation, significantly reducing the risk of the artery becoming narrowed again.

Advantages

Significantly lower restenosis rates
Better long-term clinical outcomes
Reduced need for repeat angioplasty or additional stent procedures
Excellent safety and effectiveness when combined with appropriate antiplatelet therapy

Today, Drug-Eluting Stents (DES) are the most commonly implanted coronary stents worldwide and are considered the standard of care for most patients undergoing coronary angioplasty.

3. Covered Stents

Covered stents are specialized devices that feature a metallic framework enclosed by a protective membrane or graft material. Unlike conventional stents, they are primarily used in emergency or complex coronary interventions rather than routine blockage treatment.

Common Uses

Sealing coronary artery perforations
Treating coronary artery aneurysms or pseudoaneurysms
Managing complex vascular injuries during interventional procedures
Treating selected coronary fistulas and other uncommon vascular complications

One example of this category is the Silene Covered Stent, which is specifically designed for sealing coronary perforations and managing complex vascular emergencies.

Choosing the Right Cardiac Stent

There is no single “best” cardiac stent for every patient. Factors such as the severity and location of the blockage, bleeding risk, existing medical conditions, and the ability to take long-term antiplatelet medication all influence the choice of stent. Your interventional cardiologist will recommend the most appropriate option based on your individual clinical needs.

The DGDA Price Reduction Initiative for Cardiac Stents

To improve the affordability of life-saving cardiac care, the Directorate General of Drug Administration (DGDA), Bangladesh, conducted a comprehensive review of the pricing structure of imported cardiac stents. The initiative was aimed at ensuring that patients have access to high-quality coronary stents at more reasonable prices while maintaining a sustainable market for healthcare providers and suppliers.

Factors Considered During the Price Review

Before revising the prices, the DGDA evaluated the complete cost structure associated with importing and supplying cardiac stents, including:

Import costs
Customs duties
Value Added Tax (VAT)
Distributor margins
Hospital and healthcare provider markups
Reasonable profit margins for all stakeholders

Following a detailed assessment, a specialized expert committee recommended revised maximum retail prices (MRPs) for several categories of cardiac stents.

Key Price Changes

The revised pricing resulted in noticeable reductions across multiple cardiac stent categories, making coronary interventions more affordable for patients.

Product Category	Previous Price (BDT)	New Price (BDDT)	Price Reduction
Standard Drug-Eluting Stent (DES)	60,000	57,000	3,000
Standard Drug-Eluting Stent (DES)	55,000	52,000	3,000
Standard Drug-Eluting Stent (DES)	53,500	50,000	3,500
Silene Covered Stent	109,800	62,000	47,800

Largest Stent Price After Reduction

The Silene Covered Stent experienced the most substantial price decrease.

Previous Price: BDT 109,800
Revised Price: BDT 62,000
Total Reduction: BDT 47,800

This represents an approximate 44% reduction in the maximum retail price.

Why This Matters

Cardiac stents are often required during emergency procedures such as heart attacks, where timely treatment is critical. High treatment costs can delay access to care, increasing the risk of serious complications or death.

By reducing the maximum retail prices of several cardiac stents, the DGDA aims to lessen the financial burden on patients and their families, improve access to essential cardiac interventions, and support more equitable healthcare across Bangladesh.

For many patients, these revised prices may make the difference between receiving prompt, life-saving treatment and postponing care because of financial constraints.

Best Hospitals in Bangladesh for Cardiac Stent (PCI) Treatment

Hospital	Location	Cardiac Services
National Institute of Cardiovascular Diseases (NICVD)	Dhaka	Government referral center, coronary angiography, PCI, cardiac surgery
National Heart Foundation Hospital & Research Institute	Dhaka	Angiography, angioplasty, stenting, cardiac surgery
Ibrahim Cardiac Hospital & Research Institute	Dhaka	Interventional cardiology, PCI, CABG, heart failure care
Ad-din Medical College Hospital	Dhaka	Cardiology, Coronary Care Unit (CCU), cardiology consultation; contact the hospital to confirm current angiography/PCI (stent implantation) availability at the Dhaka campus.
LABAID Cardiac Hospital	Dhaka	Coronary angioplasty, stent implantation, cardiac surgery, Cath Lab
Continental Hospital PLC	Dhaka	Comprehensive cardiac center with Cath Lab and interventional cardiology
Evercare Hospital Dhaka	Dhaka	Advanced cardiology, angioplasty, PCI, cardiac surgery
United Hospital Limited	Dhaka	Cardiac catheterization, angioplasty, heart surgery
Square Hospitals Ltd.	Dhaka	Interventional cardiology and cardiac surgery
Green Life Hospital	Dhaka	Coronary angiography, angioplasty, stenting
Ibn Sina Medical College Hospital	Dhaka	24/7 Primary PCI, angiography, angioplasty, Cath Lab
Enam Medical College & Hospital	Savar	Angiography, PCI (stenting), cardiac surgery
Zia Heart Foundation Hospital & Research Institute	Bogura	Modern Cath Lab, PCI, angioplasty, stent implantation
Rangpur Community Medical College Hospital Heart Centre	Rangpur	Angioplasty, stent placement, Primary PCI

Why Was the Price Reduction Necessary?

The decision to reduce the prices of cardiac stents in Bangladesh was driven by both growing public health concerns and the need to make life-saving heart treatments more affordable. As cardiovascular disease continues to rise across the country, ensuring access to timely and cost-effective care has become a national healthcare priority.

Rising Burden of Heart Disease

Bangladesh has experienced a significant increase in the prevalence of cardiovascular risk factors over the past decade. Lifestyle changes, urbanization, and an aging population have contributed to a growing number of people requiring specialized cardiac care.

Key contributing factors include:

Hypertension (high blood pressure)
Diabetes mellitus
Obesity and overweight
Sedentary lifestyles with limited physical activity
Smoking and tobacco-related cardiovascular disease

As a result, the number of patients requiring coronary angiography, angioplasty, and cardiac stent implantation continues to increase each year.

Reducing Financial Barriers to Treatment

For many families, the cost of coronary angioplasty remains a major financial challenge. The total expense of the procedure extends well beyond the price of the stent itself and may include:

Hospital admission and inpatient care
Diagnostic investigations and laboratory tests
Cardiac catheterization laboratory (Cath Lab) charges
Professional fees for cardiologists and healthcare staff
Medications before, during, and after the procedure
Cardiac stent implantation

Because the cardiac stent often accounts for a substantial portion of the overall treatment cost, reducing its maximum retail price can significantly lower the financial burden on patients and improve access to timely, life-saving care.

Preventing Overpricing and Improving Transparency

In addition to affordability, the revised pricing initiative aims to promote greater transparency in the healthcare system. Regulatory authorities have previously received complaints regarding:

Excessive markups on imported cardiac stents
Hidden or unexplained hospital charges
Lack of transparency in patient billing
Inadequate information about the type and price of implanted stents

The revised pricing framework seeks to address these concerns by establishing clearer maximum retail prices, encouraging fair pricing practices, and helping patients better understand the costs associated with their treatment.

Improving Access to Quality Cardiac Care

By lowering the maximum retail prices of cardiac stents, the initiative aims to ensure that more patients can receive prompt coronary intervention without facing unnecessary financial hardship. Greater affordability, combined with improved pricing transparency, has the potential to enhance access to quality cardiac care and support better health outcomes for people across Bangladesh.

DGDA’s New Transparency Requirements

Reducing the price of cardiac stents is only one part of improving patient care. To ensure that patients actually benefit from the revised pricing, the Directorate General of Drug Administration (DGDA), Bangladesh has introduced a series of mandatory transparency measures for hospitals and healthcare providers.

These requirements are designed to promote fair pricing, improve accountability, and protect patients from hidden charges or misleading billing practices.

1. Public Display of Approved Prices

Hospitals and healthcare facilities are required to prominently display the approved Maximum Retail Price (MRP) of all cardiac stents available for implantation.

This enables patients and their families to:

Verify the approved price before the procedure
Compare prices with official DGDA-approved rates
Make informed decisions regarding their treatment

2. No Bundled Billing for Stents

Under the new guidelines, hospitals are prohibited from concealing the cost of a cardiac stent within a bundled treatment package.

Instead, the stent price must be listed separately on the patient’s bill, ensuring complete transparency regarding the actual cost of the implanted device.

3. Detailed Cash Memo and Documentation

Patients must receive a separate and itemized invoice that clearly includes:

Name of the cardiac stent
Manufacturer or brand
Model or product specification
Approved Maximum Retail Price (MRP)

Providing detailed documentation helps patients verify that they have received the correct device at the approved price and creates a reliable record for future medical reference.

4. Return of the Empty Stent Packaging

Following successful implantation, hospitals are required to hand over the empty stent package to the patient or their family.

This important measure enhances product traceability by allowing patients to retain key information about the implanted device, including the manufacturer, model, batch number, and other identifying details. It also helps prevent concerns about product substitution and supports future medical follow-up if needed.

Benefits for Patients

The DGDA’s revised pricing and transparency policy offers several important advantages for patients and their families.

Improved Affordability

Lower maximum retail prices reduce out-of-pocket expenses, making coronary angioplasty more affordable for a larger number of patients.

Better Access to Life-Saving Treatment

More affordable cardiac stents can help patients receive timely coronary interventions without delaying treatment because of financial constraints.

Enhanced Pricing Transparency

Clear pricing requirements and itemized billing provide patients with greater visibility into the actual cost of their treatment, reducing confusion and unexpected expenses.

Stronger Consumer Protection

Detailed invoices, publicly displayed prices, and the return of the empty stent packaging promote accountability throughout the healthcare system. These measures help prevent overpricing, billing disputes, and unethical practices while increasing patient confidence in the quality and authenticity of the implanted medical device.

A Step Toward More Transparent Cardiac Care

Together, these reforms represent an important step toward making cardiac care in Bangladesh more affordable, transparent, and patient-centered. By combining regulated pricing with stronger documentation and disclosure requirements, the DGDA aims to ensure that patients receive both high-quality medical devices and fair treatment throughout their healthcare journey.

Impact on Hospitals and Importers

The DGDA’s revised pricing policy for cardiac stents has implications not only for patients but also for hospitals, healthcare providers, importers, and distributors. While the new regulations are intended to improve affordability and transparency, they also require stakeholders across the healthcare sector to adapt their business practices.

Impact on Hospitals

Hospitals may experience several operational and financial changes following the implementation of the revised pricing framework.

Potential impacts include:

Reduced profit margins from cardiac stent sales
Increased regulatory oversight and compliance requirements
Greater accountability in pricing, billing, and documentation
More transparent communication with patients regarding treatment costs

Although hospitals may earn less revenue per stent, lower prices could encourage more patients to undergo timely coronary interventions. An increase in the number of angioplasty procedures may help offset some of the reduction in per-procedure earnings while improving access to life-saving cardiac care.

Impact on Importers and Distributors

Importers and distributors of cardiac stents will also need to adjust to the new pricing environment.

To remain competitive and financially sustainable, companies may need to:

Optimize procurement and supply chain management
Reduce operational and administrative overhead costs
Improve inventory control and logistics
Enhance overall operational efficiency

While lower regulated prices may reduce profit margins on individual devices, increased affordability could expand the patient market and potentially lead to higher overall sales volumes.

An International Perspective

Bangladesh is not alone in regulating the prices of essential medical devices. Many countries have implemented policies to improve patient access to life-saving treatments while maintaining high standards of quality and safety.

Examples include:

India: The National Pharmaceutical Pricing Authority (NPPA) introduced price controls on cardiac stents to reduce treatment costs and improve affordability for patients.
Several European countries: Governments often negotiate prices with manufacturers or use national reimbursement systems to control healthcare spending.
Public healthcare systems worldwide: Many countries purchase medical devices through centralized procurement programs, allowing them to secure lower prices through competitive bidding and bulk purchasing.

These approaches reflect a common objective: ensuring that essential medical devices remain accessible without compromising patient safety or healthcare quality.

A Balanced Approach to Healthcare

Bangladesh’s latest cardiac stent pricing initiative aligns with a broader global trend of balancing medical innovation with affordability. By regulating prices while strengthening transparency and accountability, the policy aims to protect patients, encourage fair market practices, and improve access to advanced cardiovascular care.

As the burden of heart disease continues to rise, initiatives that promote equitable access to essential medical technologies will play an increasingly important role in improving public health outcomes.

Common Myths About Cardiac Stents

Despite significant advances in cardiovascular medicine, many misconceptions about cardiac stents continue to cause unnecessary anxiety and confusion among patients. Understanding the facts can help individuals make informed decisions about their treatment and long-term heart health.

Myth 1: A Cardiac Stent Cures Heart Disease

Reality:

A cardiac stent restores blood flow by opening a blocked coronary artery, but it does not cure coronary artery disease (CAD). The underlying condition—atherosclerosis, or the buildup of plaque inside the arteries—can continue to progress if risk factors are not properly managed.

Maintaining a heart-healthy lifestyle, taking prescribed medications, and attending regular medical follow-ups remain essential for preventing future cardiovascular events.

Myth 2: No Medication Is Needed After Stent Placement

Reality:

Stent implantation is only one part of treatment. Most patients require long-term medications to reduce the risk of complications and protect their heart health.

These commonly include:

Antiplatelet medications to help prevent blood clots inside the stent
Statins to lower cholesterol and stabilize arterial plaque
Blood pressure medications when indicated
Diabetes medications for patients with diabetes
Other heart medications based on individual clinical needs

Patients should never stop these medications without consulting their cardiologist, as doing so may increase the risk of serious complications.

Myth 3: A Stent Lasts Forever Without Follow-Up

Reality:

Although modern cardiac stents are designed to remain in the artery permanently, ongoing medical follow-up is essential.

Regular check-ups allow healthcare providers to:

Monitor overall cardiovascular health
Evaluate the effectiveness of medications
Manage blood pressure, cholesterol, and diabetes
Detect any new or recurrent coronary artery disease at an early stage

Long-term success depends on both the procedure and continued preventive care.

Myth 4: Every Coronary Blockage Requires a Stent

Reality:

Not all coronary artery blockages require stent implantation.

Depending on the severity of the disease, symptoms, and overall health, treatment options may include:

Lifestyle modifications
Medications alone
Percutaneous coronary intervention (PCI) with a cardiac stent
Coronary artery bypass graft (CABG) surgery for more complex disease

The most appropriate treatment is determined after careful evaluation by a cardiologist and should be individualized for each patient.

The Future of Cardiac Care in Bangladesh

The DGDA’s initiative to regulate cardiac stent prices represents an important step toward making advanced cardiovascular treatment more accessible and affordable. It may also serve as a model for future regulation of other high-cost medical devices and therapies.

Potential areas for future pricing and transparency initiatives include:

Pacemakers
Implantable cardioverter-defibrillators (ICDs)
Orthopedic implants, including hip and knee prostheses
High-cost oncology medicines and targeted cancer therapies
Other essential implantable medical devices

As Bangladesh continues to strengthen its healthcare system, policymakers, healthcare providers, and industry stakeholders will face the ongoing challenge of balancing medical innovation with affordability, quality, safety, and equitable access.

Conclusion

Heart disease remains one of the leading causes of illness and death in Bangladesh, making timely access to effective treatment more important than ever. The DGDA’s 2026 decision to reduce cardiac stent prices represents a major advancement in patient-centered healthcare policy. By lowering costs, enforcing transparent billing practices, and strengthening regulatory oversight, the government has taken meaningful steps toward ensuring that life-saving cardiac interventions remain accessible to a larger segment of the population.

The dramatic reduction in the price of the Silene Covered Stent, along with broader reductions across multiple stent categories, demonstrates a commitment to protecting patients from excessive healthcare costs. Equally important are the transparency measures requiring separate billing, public price displays, and proper product documentation.

For heart patients and their families, these reforms may significantly reduce financial hardship while improving trust in the healthcare system. As cardiovascular disease continues to rise in Bangladesh, such initiatives will play a crucial role in ensuring equitable access to modern cardiac treatment and ultimately improving public health outcomes nationwide.